title: High-output heart failure secondary to arteriovenous fistula.
abstract: In the hemodialysis patient population, a surgically created arteriovenous fistula is the preferred vascular access option. Development of high-output heart failure may be an underappreciated complication in patients who have undergone this procedure. When a large proportion of arterial blood is shunted from the left-sided circulation to the right-sided circulation via the fistula, the increase in preload can lead to increased cardiac output. Over time, the demands of an increased workload may lead to cardiac hypertrophy and eventual heart failure. Patients may present with the usual signs of high-output heart failure including tachycardia, elevated pulse pressure, hyperkinetic precordium, and jugular venous distension. Typically, the AV fistula is quite large and is likely located in the upper arm, more proximal to the heart. Routine access flow monitoring should demonstrate blood flows (Qa) >2000 ML/min. Echocardiogram may reveal either a low or high left ventricular ejection fraction, and right-heart catheterization demonstrates an elevated cardiac output with a low to normal systemic vascular resistance. When addressing the problem of high-output heart failure, the nephrologist is faced with the dilemma of preventing progression of heart failure at the expense of loss of vascular access. Nevertheless, treatment should be directed at correcting the underlying problem by surgical banding or ligation of the fistula.
authors.affiliation: UNC Kidney Center, Division of Nephrology and Hypertension, Chapel Hill, NC, USA.
authors.forename: Adam B
authors.initials: AB
authors.lastname: Stern
authors.affiliation: UNC Kidney Center, Division of Nephrology and Hypertension, Chapel Hill, NC, USA.
authors.forename: Philip J
authors.initials: PJ
authors.lastname: Klemmer
mesh_terms: D000328:Adult; D001164:Arteriovenous Fistula / Q000150:complications*; D005260:Female; D006333:Heart Failure / Q000209:etiology*; D006801:Humans; D006435:Renal Dialysis / Q000009:adverse effects*